HIMS Quote, Financials, Valuation and Earnings

Eli Lilly & Co. has a net margin of 2.63% compared to Hims & Hers Health, Inc.'s net margin of 31.72%. Hims & Hers Health, Inc.'s return on equity of 25.63% beat Eli Lilly & Co.'s return on equity of 106.26%.

Hims & Hers Health, Inc. has a consensus price target of $44.36, signalling upside risk potential of 27.96%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 1.51%. Given that Hims & Hers Health, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Hims & Hers Health, Inc. is more attractive than Eli Lilly & Co..

Hims & Hers Health, Inc. has a beta of 2.414, which suggesting that the stock is 141.424% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hims & Hers Health, Inc. quarterly revenues are $599M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Hims & Hers Health, Inc.'s net income of $15.8M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 64.10x while Eli Lilly & Co.'s PE ratio is 53.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 3.89x versus 16.52x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 2.63% compared to Hims & Hers Health, Inc.'s net margin of 21.32%. Hims & Hers Health, Inc.'s return on equity of 25.63% beat Pfizer Inc.'s return on equity of 10.84%.

Hims & Hers Health, Inc. has a consensus price target of $44.36, signalling upside risk potential of 27.96%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.36%. Given that Hims & Hers Health, Inc. has higher upside potential than Pfizer Inc., analysts believe Hims & Hers Health, Inc. is more attractive than Pfizer Inc..

Hims & Hers Health, Inc. has a beta of 2.414, which suggesting that the stock is 141.424% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.87% to investors and pays a quarterly dividend of $0.43 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Hims & Hers Health, Inc. quarterly revenues are $599M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Hims & Hers Health, Inc.'s net income of $15.8M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 64.10x while Pfizer Inc.'s PE ratio is 14.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 3.89x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of 2.63% compared to Hims & Hers Health, Inc.'s net margin of -3135.32%. Hims & Hers Health, Inc.'s return on equity of 25.63% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.

Hims & Hers Health, Inc. has a consensus price target of $44.36, signalling upside risk potential of 27.96%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 59.09%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than Hims & Hers Health, Inc., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than Hims & Hers Health, Inc..

Hims & Hers Health, Inc. has a beta of 2.414, which suggesting that the stock is 141.424% more volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Hims & Hers Health, Inc. quarterly revenues are $599M, which are larger than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. Hims & Hers Health, Inc.'s net income of $15.8M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 64.10x while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 3.89x versus 40.36x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of 2.63% compared to Hims & Hers Health, Inc.'s net margin of 34.76%. Hims & Hers Health, Inc.'s return on equity of 25.63% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Hims & Hers Health, Inc. has a consensus price target of $44.36, signalling upside risk potential of 27.96%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $491.92 which suggests that it could grow by 6.25%. Given that Hims & Hers Health, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Hims & Hers Health, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Hims & Hers Health, Inc. has a beta of 2.414, which suggesting that the stock is 141.424% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Hims & Hers Health, Inc. quarterly revenues are $599M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Hims & Hers Health, Inc.'s net income of $15.8M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 64.10x while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 3.89x versus 10.22x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.